Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of Cytogenetics in Management of Uveal Melanoma

Role of Cytogenetics in Management of Uveal Melanoma CONTROVERSIES Role of Cytogenetics in Management of Uveal Melanoma Jerry A. Shields, MD; Carol L. Shields, MD; Miguel Materin, MD; Takami Sato, MD; Arupa Ganguly, PhD 18,19 VEAL MELANOMA IS treatment. The increased use of eye- treatment. It is estimated that one of the few con- saving modalities, such as irradia- 1 in 5000 might evolve into mela- ditions diagnosed tion, local resection, and transpu- noma. However, if clinicians could by eye care special- pillary thermotherapy, has not identify those lesions that pose a 9,10 U ists that carries a resolved the controversy. greater risk for metastasis, then they guarded prognosis for life. Al- The philosophy of observation for might be selected for earlier treat- though most patients are appar- choroidal lesions suspected of being ment. Such risk factors for small me- ently healthy at the time of diagno- early melanomas is not in keeping lanocytic choroidal lesions have been 20,21 sis, 10-year tumor-related death from with the management of most other identified : tumor thickness of cancers. In other specialties, early de- 2 mm or larger, symptoms due to the See also pages tection and prompt treatment of pre- tumor, tumor margin near the op- malignant lesions is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Role of Cytogenetics in Management of Uveal Melanoma

Loading next page...
 
/lp/american-medical-association/role-of-cytogenetics-in-management-of-uveal-melanoma-H1O3tFyF2J

References (55)

Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.126.3.416
pmid
18332325
Publisher site
See Article on Publisher Site

Abstract

CONTROVERSIES Role of Cytogenetics in Management of Uveal Melanoma Jerry A. Shields, MD; Carol L. Shields, MD; Miguel Materin, MD; Takami Sato, MD; Arupa Ganguly, PhD 18,19 VEAL MELANOMA IS treatment. The increased use of eye- treatment. It is estimated that one of the few con- saving modalities, such as irradia- 1 in 5000 might evolve into mela- ditions diagnosed tion, local resection, and transpu- noma. However, if clinicians could by eye care special- pillary thermotherapy, has not identify those lesions that pose a 9,10 U ists that carries a resolved the controversy. greater risk for metastasis, then they guarded prognosis for life. Al- The philosophy of observation for might be selected for earlier treat- though most patients are appar- choroidal lesions suspected of being ment. Such risk factors for small me- ently healthy at the time of diagno- early melanomas is not in keeping lanocytic choroidal lesions have been 20,21 sis, 10-year tumor-related death from with the management of most other identified : tumor thickness of cancers. In other specialties, early de- 2 mm or larger, symptoms due to the See also pages tection and prompt treatment of pre- tumor, tumor margin near the op- malignant lesions is

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Mar 1, 2008

There are no references for this article.